Bristol-myers patents expiration
1. Abraxane patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6537579 | BRISTOL-MYERS | Compositions and methods for administration of pharmacologically active compounds |
Feb, 2013
(11 years ago) | |
| US6506405 | BRISTOL-MYERS | Methods and formulations of cremophor-free taxanes |
Feb, 2013
(11 years ago) | |
| US6753006 | BRISTOL-MYERS | Paclitaxel-containing formulations |
Feb, 2013
(11 years ago) | |
| US5439686 | BRISTOL-MYERS | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
Feb, 2013
(11 years ago) | |
| US6749868 | BRISTOL-MYERS | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
Feb, 2013
(11 years ago) | |
| US6096331 | BRISTOL-MYERS | Methods and compositions useful for administration of chemotherapeutic agents |
Feb, 2013
(11 years ago) | |
| US5498421 | BRISTOL-MYERS | Composition useful for in vivo delivery of biologics and methods employing same |
Mar, 2013
(11 years ago) | |
| USRE41884 | BRISTOL-MYERS | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Aug, 2016
(7 years ago) | |
| US8853260 | BRISTOL-MYERS | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
Oct, 2020
(3 years ago) | |
|
US8853260 (Pediatric) | BRISTOL-MYERS | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
Apr, 2021
(3 years ago) | |
| US8138229 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(4 months ago) | |
| US7923536 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(4 months ago) | |
| US8314156 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(4 months ago) | |
|
US8314156 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(a month from now) | |
|
US7923536 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(a month from now) | |
|
US8138229 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(a month from now) | |
| US7820788 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Oct, 2024
(5 months from now) | |
|
US7820788 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Apr, 2025
(11 months from now) | |
| US7758891 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 9 months from now) | |
| US8268348 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 9 months from now) | |
| US9101543 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 9 months from now) | |
| US8034375 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US7758891 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US9101543 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US8268348 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US8034375 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2027
(2 years from now) | |
| US9393318 | BRISTOL-MYERS | Methods of treating cancer |
Mar, 2032
(7 years from now) | |
| US9597409 | BRISTOL-MYERS | Methods of treating cancer |
Mar, 2032
(7 years from now) | |
|
US9393318 (Pediatric) | BRISTOL-MYERS | Methods of treating cancer |
Sep, 2032
(8 years from now) | |
|
US9597409 (Pediatric) | BRISTOL-MYERS | Methods of treating cancer |
Sep, 2032
(8 years from now) | |
| US9511046 | BRISTOL-MYERS | Methods of treating pancreatic cancer |
Jan, 2034
(9 years from now) | |
|
US9511046 (Pediatric) | BRISTOL-MYERS | Methods of treating pancreatic cancer |
Jul, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
| M(M-14) | Dec 06, 2022 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| New Indication(I-658) | Oct 11, 2015 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of breast cancer; Method for treatment of tumors by administering paclitaxel at a dose in the range of about 30mg/meter square to about 100mg/meter square in a pharmaceutically acceptable fo...
Dosage: POWDER;INTRAVENOUS
ABRAXANE family patents
2. Inrebic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7825246 | BRISTOL-MYERS | Bi-aryl meta-pyrimidine inhibitors of kinases |
Dec, 2026
(2 years from now) | |
| US7528143 | BRISTOL-MYERS | Bi-aryl meta-pyrimidine inhibitors of kinases |
Nov, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8138199 | BRISTOL-MYERS | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
Jun, 2028
(4 years from now) | |
| US10391094 | BRISTOL-MYERS | Compositions and methods for treating myelofibrosis |
Jun, 2032
(8 years from now) | |
| US11400092 | BRISTOL-MYERS | Methods of treating myeloproliferative disorders |
Sep, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-259) | Aug 16, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis; Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring...
Dosage: CAPSULE;ORAL
INREBIC family patents
3. Istodax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US4977138 | BRISTOL-MYERS | FR901228 substance and preparation thereof |
Aug, 2013
(10 years ago) | |
| US7611724 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(2 years ago) | |
| US7608280 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-12) | Jun 16, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2014 |
| Orphan Drug Exclusivity(ODE) | Jun 16, 2018 |
Drugs and Companies using ROMIDEPSIN ingredient
NCE-1 date: 05 November, 2013
Market Authorisation Date: 05 November, 2009
Treatment: NA
Dosage: POWDER;INTRAVENOUS
ISTODAX family patents
4. Thalomid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6235756 | BRISTOL-MYERS | Methods and compositions for inhibition of angiogenesis by thalidomide |
Mar, 2013
(11 years ago) | |
| US7723361 | BRISTOL-MYERS | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide |
Mar, 2013
(11 years ago) | |
| US8143283 | BRISTOL-MYERS | Methods for treating blood-born tumors with thalidomide |
Mar, 2013
(11 years ago) | |
| US5629327 | BRISTOL-MYERS | Methods and compositions for inhibition of angiogenesis |
May, 2014
(9 years ago) | |
| US7435745 | BRISTOL-MYERS | Methods and compositions for inhibition of angiogenesis |
Nov, 2017
(6 years ago) | |
| US6561976 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US8204763 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6045501 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US7874984 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6908432 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US8589188 | BRISTOL-MYERS | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6755784 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US8626531 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US7959566 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6561977 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6315720 | BRISTOL-MYERS | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(3 years ago) | |
| US8315886 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6869399 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US7141018 | BRISTOL-MYERS | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US7230012 | BRISTOL-MYERS | Pharmaceutical compositions and dosage forms of thalidomide |
Dec, 2023
(4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 23, 2013 |
Drugs and Companies using THALIDOMIDE ingredient
Market Authorisation Date: 16 July, 1998
Treatment: Use in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma; Use of thalidomide in combination with dexamethasone for the treatment of patien...
Dosage: CAPSULE;ORAL
THALOMID family patents